257 related articles for article (PubMed ID: 17125279)
1. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.
Fancelli D; Moll J; Varasi M; Bravo R; Artico R; Berta D; Bindi S; Cameron A; Candiani I; Cappella P; Carpinelli P; Croci W; Forte B; Giorgini ML; Klapwijk J; Marsiglio A; Pesenti E; Rocchetti M; Roletto F; Severino D; Soncini C; Storici P; Tonani R; Zugnoni P; Vianello P
J Med Chem; 2006 Nov; 49(24):7247-51. PubMed ID: 17125279
[TBL] [Abstract][Full Text] [Related]
2. Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
Bindi S; Fancelli D; Alli C; Berta D; Bertrand JA; Cameron AD; Cappella P; Carpinelli P; Cervi G; Croci V; D'Anello M; Forte B; Giorgini ML; Marsiglio A; Moll J; Pesenti E; Pittalà V; Pulici M; Riccardi-Sirtori F; Roletto F; Soncini C; Storici P; Varasi M; Volpi D; Zugnoni P; Vianello P
Bioorg Med Chem; 2010 Oct; 18(19):7113-20. PubMed ID: 20817473
[TBL] [Abstract][Full Text] [Related]
3. Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.
Prime ME; Courtney SM; Brookfield FA; Marston RW; Walker V; Warne J; Boyd AE; Kairies NA; von der Saal W; Limberg A; Georges G; Engh RA; Goller B; Rueger P; Rueth M
J Med Chem; 2011 Jan; 54(1):312-9. PubMed ID: 21128645
[TBL] [Abstract][Full Text] [Related]
4. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
Brasca MG; Albanese C; Alzani R; Amici R; Avanzi N; Ballinari D; Bischoff J; Borghi D; Casale E; Croci V; Fiorentini F; Isacchi A; Mercurio C; Nesi M; Orsini P; Pastori W; Pesenti E; Pevarello P; Roussel P; Varasi M; Volpi D; Vulpetti A; Ciomei M
Bioorg Med Chem; 2010 Mar; 18(5):1844-53. PubMed ID: 20153204
[TBL] [Abstract][Full Text] [Related]
5. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors.
Moriarty KJ; Koblish HK; Garrabrant T; Maisuria J; Khalil E; Ali F; Petrounia IP; Crysler CS; Maroney AC; Johnson DL; Galemmo RA
Bioorg Med Chem Lett; 2006 Nov; 16(22):5778-83. PubMed ID: 16949284
[TBL] [Abstract][Full Text] [Related]
6. Discovery of pyrrole-indoline-2-ones as Aurora kinase inhibitors with a different inhibition profile.
Chiang CC; Lin YH; Lin SF; Lai CL; Liu C; Wei WY; Yang SC; Wang RW; Teng LW; Chuang SH; Chang JM; Yuan TT; Lee YS; Chen P; Chi WK; Yang JY; Huang HJ; Liao CB; Huang JJ
J Med Chem; 2010 Aug; 53(16):5929-41. PubMed ID: 20681538
[TBL] [Abstract][Full Text] [Related]
7. 3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors.
Pevarello P; Fancelli D; Vulpetti A; Amici R; Villa M; Pittalà V; Vianello P; Cameron A; Ciomei M; Mercurio C; Bischoff JR; Roletto F; Varasi M; Brasca MG
Bioorg Med Chem Lett; 2006 Feb; 16(4):1084-90. PubMed ID: 16290148
[TBL] [Abstract][Full Text] [Related]
8. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.
Soncini C; Carpinelli P; Gianellini L; Fancelli D; Vianello P; Rusconi L; Storici P; Zugnoni P; Pesenti E; Croci V; Ceruti R; Giorgini ML; Cappella P; Ballinari D; Sola F; Varasi M; Bravo R; Moll J
Clin Cancer Res; 2006 Jul; 12(13):4080-9. PubMed ID: 16818708
[TBL] [Abstract][Full Text] [Related]
9. Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.
Menichincheri M; Albanese C; Alli C; Ballinari D; Bargiotti A; Caldarelli M; Ciavolella A; Cirla A; Colombo M; Colotta F; Croci V; D'Alessio R; D'Anello M; Ermoli A; Fiorentini F; Forte B; Galvani A; Giordano P; Isacchi A; Martina K; Molinari A; Moll JK; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pillan A; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Vianello P; Volpi D; Santocanale C; Vanotti E
J Med Chem; 2010 Oct; 53(20):7296-315. PubMed ID: 20873740
[TBL] [Abstract][Full Text] [Related]
10. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
Brasca MG; Amboldi N; Ballinari D; Cameron A; Casale E; Cervi G; Colombo M; Colotta F; Croci V; D'Alessio R; Fiorentini F; Isacchi A; Mercurio C; Moretti W; Panzeri A; Pastori W; Pevarello P; Quartieri F; Roletto F; Traquandi G; Vianello P; Vulpetti A; Ciomei M
J Med Chem; 2009 Aug; 52(16):5152-63. PubMed ID: 19603809
[TBL] [Abstract][Full Text] [Related]
11. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of new potent anticancer pyrazoles with high FLT3 kinase inhibitory selectivity.
El-Deeb IM; Lee SH
Bioorg Med Chem; 2010 Jun; 18(11):3961-73. PubMed ID: 20472440
[TBL] [Abstract][Full Text] [Related]
13. Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition.
Fancelli D; Berta D; Bindi S; Cameron A; Cappella P; Carpinelli P; Catana C; Forte B; Giordano P; Giorgini ML; Mantegani S; Marsiglio A; Meroni M; Moll J; Pittalà V; Roletto F; Severino D; Soncini C; Storici P; Tonani R; Varasi M; Vulpetti A; Vianello P
J Med Chem; 2005 Apr; 48(8):3080-4. PubMed ID: 15828847
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents.
Li X; Lu X; Xing M; Yang XH; Zhao TT; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Jun; 22(11):3589-93. PubMed ID: 22572580
[TBL] [Abstract][Full Text] [Related]
15. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.
Mortlock AA; Foote KM; Heron NM; Jung FH; Pasquet G; Lohmann JJ; Warin N; Renaud F; De Savi C; Roberts NJ; Johnson T; Dousson CB; Hill GB; Perkins D; Hatter G; Wilkinson RW; Wedge SR; Heaton SP; Odedra R; Keen NJ; Crafter C; Brown E; Thompson K; Brightwell S; Khatri L; Brady MC; Kearney S; McKillop D; Rhead S; Parry T; Green S
J Med Chem; 2007 May; 50(9):2213-24. PubMed ID: 17373783
[TBL] [Abstract][Full Text] [Related]
16. Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines.
Manetti F; Brullo C; Magnani M; Mosci F; Chelli B; Crespan E; Schenone S; Naldini A; Bruno O; Trincavelli ML; Maga G; Carraro F; Martini C; Bondavalli F; Botta M
J Med Chem; 2008 Mar; 51(5):1252-9. PubMed ID: 18257513
[TBL] [Abstract][Full Text] [Related]
17. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships.
Vanotti E; Amici R; Bargiotti A; Berthelsen J; Bosotti R; Ciavolella A; Cirla A; Cristiani C; D'Alessio R; Forte B; Isacchi A; Martina K; Menichincheri M; Molinari A; Montagnoli A; Orsini P; Pillan A; Roletto F; Scolaro A; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C
J Med Chem; 2008 Feb; 51(3):487-501. PubMed ID: 18201066
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles and pyrazolo[3,4-b]pyridines for Aurora-A kinase inhibitors.
Shi J; Xu G; Zhu W; Ye H; Yang S; Luo Y; Han J; Yang J; Li R; Wei Y; Chen L
Bioorg Med Chem Lett; 2010 Jul; 20(14):4273-8. PubMed ID: 20621733
[TBL] [Abstract][Full Text] [Related]
19. Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.
Bussenius J; Anand NK; Blazey CM; Bowles OJ; Bannen LC; Chan DS; Chen B; Co EW; Costanzo S; DeFina SC; Dubenko L; Engst S; Franzini M; Huang P; Jammalamadaka V; Khoury RG; Kim MH; Klein RR; Laird D; Le DT; Mac MB; Matthews DJ; Markby D; Miller N; Nuss JM; Parks JJ; Tsang TH; Tsuhako AL; Wang Y; Xu W; Rice KD
Bioorg Med Chem Lett; 2012 Mar; 22(6):2283-6. PubMed ID: 22342124
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
